Journal
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
Volume 449, Issue 1-2, Pages 8-16Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.abb.2006.02.023
Keywords
MAPK; ERK2; docking; p38; JNK
Categories
Funding
- NIDDK NIH HHS [DK34128] Funding Source: Medline
- NIGMS NIH HHS [GM62890] Funding Source: Medline
Ask authors/readers for more resources
We showed previously that p90 RSK was activated in cells expressing an activated mutant of MEK5, the activator of the MAP kinase ERK5. Based on the following evidence, we suggest that ERK5 can directly activate RSK in cells. ERK5 binds to RSK in vitro and coimmunoprecipitates from cell extracts; activation of ERK5 weakens its binding to RSK, suggesting that RSK is released upon activation. Phosphorylation of RSK by ERK5 in vitro causes its activation, indicating that RSK is a substrate of ERK5. In cells activation of ERK5 but not p38 or the c-Jun N-terminal kinase is associated with RSK activation. The large C-terminal domain of ERK5 is not required for binding or activation of RSK by ERK5; however, the common docking or CD domain of ERK5 and the docking or D domain of RSK are important for their association. (c) 2006 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available